CT Imaging for Guiding PA-TACE for HCC

CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06156748

Enrollment

1770

Registered

2023-12-05

Start date

2019-10-01

Completion date

2025-06-30

Last updated

2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Keywords

Carcinoma, Hepatocellular

Brief summary

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Interventions

PROCEDUREpostoperative adjuvant transarterial chemoembolization

HCC patients received hepatectomy and PA-TACE.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* CT scans acquired no more than one month before surgery * Confirmation of HCC diagnosis by pathological examination * Curative surgical resection

Exclusion criteria

* Prior antitumor treatment * Macrovascular thrombosis or metastasis * Perioperative mortality * Unqualified image artifacts * Tumor rupture * MVI status not reported

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.	Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026